KaloBios to Present at 29th Annual ROTH Conference

BRISBANE, Calif., March 09, 2017 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. KBIO, a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced that Cameron Durrant, MD, chairman and CEO, will present a company overview at the 29th Annual ROTH Conference.

The ROTH conference will be held March 12-15, 2017, at The Ritz-Carlton, Laguna Niguel, in Dana Point, Calif.

For more information on the conference, please visit www.roth.com/main/Page.aspx?PageID=7280.

About KaloBios Pharmaceuticals, Inc.

KaloBios Pharmaceuticals, Inc. KBIO is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab (formerly KB004), for the potential treatment of various solid and hematologic cancers such as CMML and potentially JMML. For more information, visit www.kalobios.com.

CONTACT:

Investors:
Mike Cole
O: 949-259-4988
C: 949-444-1341
mike.cole@mzgroup.us

Media:
Lisa Guiterman
O: 301-217-9353
C: 202-330-3431
media@kalobios.com